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Abstract
Background: Abdominal obesity is associated with pro-thrombotic and inflammatory states.
Therefore, the purpose of this study was to examine the expression of thrombin receptors (PAR1
and PAR4) human adipose tissue and whether thrombin stimulates an inflammatory cytokine and
growth factor profile in human adipose tissue.
Methods: Human adipose tissue, isolated preadipocytes and differentiated adipocytes were used
in this study. PAR1 and PAR4 mRNA and protein were detected by RT-PCR and immunoblot
analysis in both adipose tissue and adipose microvessels. In separate studies, IL-1β, IL-6, MCP-1,
TNF-α, IL-10, FGF-2, VEGF, and PDGF production were measured from adipose tissue (n = 5),
adipocytes (n = 5), and preadipocytes (n = 3) supernatants with and without thrombin (1 or 10 U/
ml; 24 hrs) treatment.
Results: Thrombin increased cytokine secretion of IL-1β, IL-6, MCP-1 and TNF-α and growth
factor secretion of VEGF from adipocytes along with MCP-1 and VEGF from preadipocytes. The
direct thrombin inhibitor lepirudin given in conjunction with thrombin prevented the thrombin-
mediated increase in cytokine and growth factor secretion.
Conclusion: Here we show that thrombin PAR1 and PAR4 receptors are present and that
thrombin stimulates inflammatory cytokine generation and growth factor release in human adipose
tissue and cells in vitro. These data suggest that thrombin may represent a molecular link between
obesity and associated inflammation.
Background
Protease-Activated Receptors (PAR) belongs to a small
family of seven transmembrane G protein-coupled recep-
tors (GCPR) whose unique mechanism of action requires
proteolytic cleavage of the N-terminus. This cleavage
exposes a tethered ligand which then transactivates the
receptor [1,2]. Serine proteases including thrombin and
other coagulation factors such as Factor (F) Xa and the Tis-
sue Factor (TF):FVIIa complex activate PAR1 and/or PAR4
[3,4]. PARs have been found to be expressed in a variety of
tissues and cells including platelets, endothelial cells, leu-
kocytes, and fibroblasts and modulate a variety of
responses to thrombin including fibrosis, thrombosis,
and inflammation [3].
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PAR activation in non-adipose tissue induces the hall-
marks of inflammation, including up-regulation of proin-
flammatory mediators and adhesion molecules,
enhanced vascular permeability and leukocyte extravasa-
tion and infiltration [5,6]. Specifically, thrombin stimu-
lates production of the proinflammatory cytokines
interleukin (IL)-1, IL-6, and monocyte chemotactic pro-
tein (MCP)-1 from vascular endothelial cells [7-9]. Simi-
larly, thrombin activation of monocytes increases the
secretion of tumor necrosis factor (TNF)-α, IL-1β, IL-6,
and MCP-1 [9-11]. Thrombin also stimulates angiogeneis
and contributes to the increased expression of angiogenic
growth factors including fibroblast growth factor (FGF)-2,
platelet derived growth factor (PDGF) and vascular
endothelial growth factor (VEGF) [7,12-14]. The inflam-
matory and angiogenic properties of thrombin have
important roles in the pathogenesis of atherosclerosis
[15]. However, it is unknown what role these receptors
play in modulating the inflammatory response associated
with adipose tissue accumulation.
Abdominal adipose mass is associated with the metabolic
syndrome representing a compilation of abnormalities
including insulin resistance, hyperlipidemia, hyperten-
sion, and atherosclerosis leading to cardiovascular disease
[16]. Excess and/or dysfunctional adipose tissue, particu-
larly visceral adipose tissue is associated with a chronic
low-grade systemic inflammation. Hypercoagulation is
also associated with obesity and the metabolic syndrome
[17,18] such that the levels of PAR activating proteases
(e.g. thrombin, TF, FVIIa, and FXa) are elevated [18-22].
However, the contribution of coagulation factors such as
thrombin to adipose-mediated inflammation is
unknown.
In this study, we tested the hypothesis that thrombin
receptors are expressed in adipose tissue and that
thrombin modulates inflammatory cytokine and ang-
iogenic growth factor release in human adipose tissue and
cells.
Methods
Subjects
Discarded and de-identified visceral adipose samples were
obtained from 16 patients at the time of abdominal sur-
gery. The patients ages ranged from 34 – 64 years old with
one patient > 80 years old and BMI ranged from 19.5 –
33.5 (average 25.9). Since the tissues used were otherwise
discarded and de-identified during the surgical procedure
we were unable to ascertain the specific criteria used to
make the diagnosis or quantify the severity and duration
of medical therapy, if any. Most surgeries were done for
bowel resections, liver resections or exploratory laparo-
scopies as a result of trauma. None of the patients had car-
diovascular disease. All studies were approved by the
institutional IRB committee. Adipose tissue was used for
acute adipose tissue culture and isolation of the stromal-
vascular (S-V) fraction.
Materials
All cell cultureware were purchased from Fisher Scientific
(Norcross, GA). Bacterial collagenase Clostridium histolyti-
cum (type 1) was obtained from Worthington Biochemi-
cals (Lakewood, NJ). 1× RBC Lysis Buffer was obtained
from eBioscience (San Diego, CA). Media and supple-
ments were purchased from PromoCell (Heidelberg, Ger-
many). Fatty-Acid Free (FAF)-bovine serum albumin
(BSA) and human thrombin was obtained from Sigma
(St. Louis, MO) along with all other chemicals and rea-
gents unless otherwise stated.
Human Adipose Tissue and Cell Culture
Human adipose tissue pieces contain the different cell
types including fibroblasts, endothelial and adipose cells
and permit long-term culture [23]. Thus, primary culture
of adipose tissue pieces preserves paracrine interaction
among cells that can influence adipocyte metabolism and
offers the unique possibility to study this interaction in
culture. Preparation of adipose tissue cultures was per-
formed as previously described [23]. Briefly, adipose tis-
sue was minced into small pieces (2–4 mm2) using
scissors under aseptic conditions. The minced tissue was
washed twice in HBSS/2% FAF-BSA by centrifuging at 450
g × 5 min followed by pouring the minced tissue through
a 200 μm nylon mesh and rinsing with 300 ml sterile PBS.
The explants (0.5 mg/ml) were incubated for the indi-
cated times in suspension culture under aseptic condi-
tions at 37°C and 5% (v/v) CO2.
The S-V cell fraction was isolated as previously described
[24]. In brief, minced adipose tissue (1–3 grams) was
washed twice and then placed in digestion solution (200
U/ml collagenase, 1% FAF-BSA, and PBS to 10 ml) in a
shaker (200 rpm) at 37°C for 1 hr. The collagenase digest
was separated from undigested tissue, adipocytes and lip-
ids by centrifugation at 850 g × 5 min. The pellet contain-
ing the S-V cell fraction was then resuspended in 10 ml 1×
RBC Lysis Buffer and incubated for 10 min at room tem-
perature. The sample was centrifuged again and the cell
pellet was resuspended in PromoCell Preadipocyte
Growth Medium. The cells were cultured on non-coated
plates to limit adherence of endothelium thereby enrich-
ing the environment for preadipocytes. Preadipocytes
were differentiated at passage 3 by adding PromoCell Adi-
pocyte Differentiation Medium for 72 hrs and then fur-
ther culturing the cells in PromoCell Adipocyte Growth
Medium until differentiation was complete (12–14 days).
The life-span of unstimulated macrophages in culture is
5–6 days [25]. At the time of the experiments more than
70% of the primary culture cells were filled with multipleJournal of Inflammation 2009, 6:4 http://www.journal-inflammation.com/content/6/1/4
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lipid droplets. The lipid accumulations in the differenti-
ated adipocytes were assessed through staining of the neu-
tral fats and cholesterol esters using Oil Red O dye
(Sigma). In brief, the differentiated adipocytes were fixed
in 4% formaldehyde for 10 min, and then stained for 30
min with the Oil Red O dye dissolved in isopropanol. The
stained adipocytes were washed with PBS.
Protein Extraction for Immunoblot Analysis
Adipose tissue was dissected free of microvessels and
fibrous tissue. The dissected microvessels and adipose tis-
sue were put into separate tubes and flash frozen in liquid
nitrogen. Ice-cold RIPA buffer (50 mM Tris-HCL, pH 7.5,
1% Nonidet P-40, 0.1 mM EDTA, 0.1 mM EGTA, 0.1%
SDS, 0.1% deoxycholic acid) was added and the tissue was
homogenized for 15 strokes and centrifuged at 10,000 × g
at 4°C for 10 min. Protein concentration was measured
by the bicinchoninic acid protein assay.
Immunoblot Analysis
Fifty micrograms of protein from each sample was mixed
with 10× reducing SDS loading buffer, boiled for 5 min-
utes, run on a 10% polyacrylamide SDS gel and trans-
ferred to a PVDF membrane. After the membrane was
blocked for 1 hr at room temperature with 5% non-fat
milk in TBS with 0.1% Tween-20 (TBS-T), it was incu-
bated with a 1:200 dilution of the primary antibody (Anti-
Thrombin Receptor (PAR1), Cat No. 611523BD, Bio-
sciences, San Jose, CA or PAR4 (C-20), Cat No. sc-8464,
Santa Cruz, CA) in TBS containing 0.1% Tween-20, 0.5%
dry milk and 0.1% sodium azide overnight at 4°C. The
blots were then incubated with the secondary antibody
for 1 hr at room temperature, followed with enhanced
chemiluminescence solution (Amersham Life Science,
Arlington Heights, IL) and then exposed to film for 1
minute. Cell lysates from the A549 cell line (ProSci Incor-
porated, Poway, CA) was used for a positive control.
RT-PCR
Forward and reverse primers used for amplifying human
PAR1 and PAR4 were prepared commercially, based on
published data (accession number NM_001992 and
NM_003950): PAR1 sense 5'-CCGCCTGCTTCAGTCTGT-
3', antisense 5'-TCATCCTCCCAAAATGGTTC-3' (PCR
product 151 bp) and PAR4 sense 5'-CAGAGCAGCCT-
GAGTGCAG-3' and antisense 5'-CAGGGTGTCACTGT-
CATTGG-3' (PCR product 207). The conditions for
amplification were 95°C for 2 min for one cycle, 95°C for
30 s, 62°C for 30 s, 72°C for 60 s for 30 cycles and 72°C
for 1 min for 1 cycle. Two microliters of cDNA was used
in each reaction along with iTaq DNA Polymerase and
dNTP mix (Bio-Rad, Hercules, CA). Electrophoresis was
conducted on a 2% agarose gel stained with SYBR green.
Thrombin Stimulation of Adipose Tissue, Adipocytes and, 
Preadipocytes
Confluent cells were washed twice with PBS and then
incubated with Starvation Media (DMEM/F12 with d-
Biotin 8 μg/ml and bovine insulin (0.5 μg/ml). After 6
hours, the media was replaced with fresh Starvation
Media containing PBS, IBMX (100 μM), or thrombin (1 or
10 U/ml) or thrombin (10 U/ml) and lepirudin (100
ATU/ml). Minced adipose tissue samples were cultured in
Assay Buffer (Zen-Bio, Inc, Research Triangle Park, NC)
with PBS, thrombin (1 U/ml) or thrombin (10 U/ml)
with or without lepirudin (100 ATU/ml). After 24 hours,
conditioned medium was collected and stored at -80°C
until analysis. Interleukin-1β, IL-6, TNF-α, MCP-1, IL-10,
FGF-2, PDGF-BB, and VEGF were determined in duplicate
by a human cytokine Bioplex assay using a custom kit
from BioRad (Hercules, CA).
Statistical Analysis
Data are reported as mean ± SEM. Statistical analyses were
performed by the Student's t test for paired values and a
one-way Analysis of Variance (ANOVA) for differences
between treatment groups. If significant, a Newman-Keuls
multiple comparison test was used to perform pair wise
comparisons. Data were considered significant at a p <
0.05. Statistics were performed using WINKS SDA Soft-
ware (Texasoft, Cedar Hill, TX).
Results
PAR1 and PAR4 Expression in Adipose Tissue
cDNA reverse transcribed from adipose tissue mRNA from
5 individuals was amplified using primers specific for the
human PAR1 and PAR4 sequences. PAR1 mRNA is consti-
tutively expressed in the human adipose tissue (Figure 1A,
lanes 1–5). PAR4 mRNA is also detected in human adi-
pose tissue (Figure 1B, lanes 1–5). Human adipose tissue
from 6 individuals was dissected free of microvessel and
protein was extracted from both the adipose tissue and
microvessels and used for immunoblotting for PAR1 and
PAR4. A representative immunoblot of tissue from 2 indi-
viduals is shown in Figure 1C. Both PAR1 and PAR4 were
detected in both adipose tissue and the microvessels.
When equalized for protein loading, PAR1 protein was
higher in the adipose vasculature. While PAR4 is more
prominent in adipose tissue than microvessels, to further
localize the cell type expressing PAR1 or PAR4, adipose
tissue tissues from the same 6 individuals were digested
and the S-V fraction was isolated. The S-V fraction was
split and cultured as preadipocytes or differentiated into
adipocytes cells. A representative immunoblot of the cell
lysates from adipocytes and preadipocytes from 2 individ-
uals is shown in Figure 1C. The presence of PAR4, but not
PAR1 is detected.Journal of Inflammation 2009, 6:4 http://www.journal-inflammation.com/content/6/1/4
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Effect of Thrombin on Pro-Inflammatory Cytokine 
Secretion
The effect of thrombin on pro-inflammatory cytokine
secretion was assessed using human adipose tissue, adi-
pocytes, and preadipocytes cultures (Table 1 and Figure
2). Both 1 U/ml and 10 U/ml thrombin was used to stim-
ulate the cultures; however the 1 U/ml thrombin concen-
tration failed to induce a significant cytokine secretion.
Thrombin (10 U/ml) increased the secretion from differ-
entiated adipocytes but not preadipocytes or adipose tis-
sue (Figure 2A). In addition, the direct thrombin
inhibitor, lepirudin completely abolished the IL-β pro-
duction by thrombin (10 U/ml) in these cultures.
Thrombin (10 U/ml) also enhanced IL-6 release in adi-
pocytes and preadipoctyes (Figure 2B). The basal secre-
tion from preadipocytes was lower than the basal
secretion from adipocytes. Lepirudin completely abol-
ished thrombin-mediated secretion of IL-6 from adipose
tissue, adipocytes and preadipocytes. Thrombin (10 U/
ml) stimulation of adipocyte cultures increased TNF-α
secretion and MCP-1 secretion, and increased preadi-
pocyte MCP-1 release (Figure 2C and Figure 2D). Lepiru-
din abolished these responses.
Effect of Thrombin on Anti-Inflammatory Cytokine 
Secretion
Secretion of IL-10 from thrombin (1 and 10 U/ml) stimu-
lated adipose tissue, adipocytes and preadipocytes was
below the detection limit (data not shown).
PAR1 and PAR4 are present in adipose tissue Figure 1
PAR1 and PAR4 are present in adipose tissue. A) PAR1 mRNA amplified from cDNA from adipose tissue from 5 individ-
uals (lanes 1–5). The positive control (lane 6) contains cDNA from a human artery and the negative control (lane 7) contains 
PAR1 specific primers but no cDNA. B) PAR4 mRNA amplified from cDNA from adipose tissue from 5 individuals (lanes 1–5). 
The positive control (lane 6) contains cDNA from a human artery and the negative control (lane 7) contains PAR4 specific 
primers but no cDNA. C) Representative immunoblots of tissue or cells from 2 individuals (A and B). PAR1 and PAR4 protein 
detected in adipose tissue (lanes 2 and 4) and adipose microvessels (lanes 3 and 4) but only PAR4 is detected in Preadipocytes 
(lanes 7 and 9) and differentiated adipocytes (lanes 8 and 10). Lane 1 is a positive control lysate. Lane 6 contains the molecular 
weight marker. A total of 6 groups (whole tissue and isolated preadipocytes and differentiated adipocytes) were analyzed for 
PAR1 and PAR4.
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Thrombin stimulates inflammatory cytokine secretion predominately from primary cultures of newly differentiated human adi- pocytes Figure 2
Thrombin stimulates inflammatory cytokine secretion predominately from primary cultures of newly differen-
tiated human adipocytes. Cultures of adipose tissue (n = 5), newly differentiated adipocytes (n = 5) or preadipocytes (n = 
3) were stimulated with thrombin (1 U/ml) or thrombin (10 U/ml) in the presence or absence of a thrombin inhibitor (lepiru-
din) for 24 hours. PBS served as the negative control. The following cytokines were measured from the supernatants of conflu-
ent cultures. A) IL-1β; B) IL-6; C) TNF-α; D) MCP-1. Means ± SEM,. *P < 0.05 thrombin vs. PBS. ± P < 0.05 thrombin + 
lepirudin vs. thrombin.
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The Effect of Thrombin on Growth Factor Secretion
Human adipose tissue explants, adipocytes, and preadi-
pocytes cultures were also used to assess the effects of
thrombin on angiogenic growth hormone secretion
(Table 1 and Figure 3). Again 1 U/ml and 10 U/ml
thrombin concentrations were used to stimulate the cells,
yet no significant stimulation was found with the lower
concentration. Thrombin (10 U/ml) increased FGF-2
secretion from adipocytes and PDGF secretion from adi-
pocytes and preadipocytes (Figure 3A and Figure 3B). The
addition of lepirudin reversed these effects. Additionally,
thrombin (10 U/ml) enhanced VEGF secretion in adipose
tissue and adipocytes and preadipocyte cultures (Figure
3C). Again this secretion was diminished by lepirudin.
Discussion
There are three novel findings of this study. First, our
results indicate that thrombin PAR1 and PAR4 receptors
are present in adipose tissue. Second, thrombin stimu-
lated secretion of pro-inflammatory (IL-1β, IL-6, MCP-1,
and TNF-α) cytokines in human adipocytes, an effect that
was blocked by the thrombin inactivating peptide lepiru-
din. Third, thrombin induced secretion of the major ang-
iogenic growth hormones, FGF-2 PDGF, and VEGF from
adipocytes and PDGF and VEGF from preadipocytes.
Again, these effects were blocked by lepirudin. Taken
together these data suggest that thrombin modulates the
inflammatory and angiogenic status of adipose tissue.
Thrombin Receptors in Adipose Tissue
Our studies indicate that PAR1 is expressed primarily in
the microvasculature of the adipose tissue rather than in
the adipocytes. In contrast, PAR4 is expressed in the non-
vascular cells in human adipose tissue. These findings are
similar to other reports indicating PAR1 is the predomi-
nant thrombin receptor in human vasculature [26]. How-
ever, this is the first study to show that PAR4 is
preferentially expressed in human preadipocytes and adi-
pocytes suggesting that the thrombin-mediated responses
of these cells are mediated by PAR4 activation.
Characterization of Cultures
The various cell types within adipose tissue including adi-
pocytes, preadipocytes, fibroblasts, macrophages, and
vascular cells are able to contribute to the secretion of
cytokines and growth factors [27,28]. Each cell type con-
tributes to the cytokine footprint under different condi-
tions and stimuli. Therefore, we stimulated both isolated
preadipocytes and differentiated adipocytes (from the
same tissue) with thrombin to determine which cell type
contributes to the secretion of cytokines and growth fac-
tors. We have shown that thrombin preferentially stimu-
lates the secretion of IL-1β, IL-6, and TNF-α from
differentiated adipocytes. It has previously been shown,
that unstimlutated non-adipocytes contribute the major-
ity of basal IL-1β, IL-6, and TNF-α secretion [28]. There-
fore, either thrombin is able to shift the balance in
cytokine secretion from non-adipoctyes to adipocytes or
this finding may be attributed to the differences in exper-
imental design. In the work by Fain et al., the cytokine lev-
els were measured within 48 hours of adipocytes and S-V
cells isolation when macrophages and endothelial cell
numbers are relatively high in the S-V fraction [28]. How-
ever, it is unlikely that macrophages were involved in the
Table 1: Secretion of cytokines and growth hormones after stimulation of adipose tissue, differentiated adipocytes, or pre-adipocytes 
with thrombin.
Adipocytes
n = 5
Preadipocytes
n = 3
Adipose Tissue
n = 5
IL-1 24 h secretion 2.0 ± 1a 0.2 ± 0.1 1062 ± 721
% induction 616 ± 341 717 ± 453 195 ± 74
IL-6 24 h secretion 4638 ± 1756a 272 ± 201a 54682 ± 10734
% induction 3100 ± 1400 2274 ± 1041 22 ± 13
TNF- 24 h secretion 7.7 ± 4.5a 0.5 ± 0.5 168 ± 97
% induction 906 ± 522 25 ± 20 44 ± 30
MCP-1 24 h secretion 521 ± 167a 951 ± 577a 14421 ± 6996
% induction 520 ± 370 2451 ± 842 144 ± 64
FGF-2 24 h secretion 4.8 ± 2.1a 1.3 ± 1.2 287 ± 104
% induction 195 ± 106 52 ± 44 202 ± 140
PDGF 24 h secretion 1.4 ± 0.9a 0.7 ± 0.3a 170 ± 144
% induction 198 ± 28 635 ± 131 77 ± 52
VEGF 24 h secretion 4662 ± 1884a 13465 ± 10177a 3783 ± 609a
% induction 401 ± 96 634 ± 131 134 ± 87
Differentiated Adipocytes, Preadipocytes or Adipose Tissue cultures were incubated for 24 h in the presence of thrombin (10 U/ml). Cytokine and 
growth factor release to the medium is in pg/ml for adipocytes and preadipocyte cultures and pg/ml/g for adipose tissue cultures. % induction is the 
average of the individual % cytokine/growth factor induction from each sample. The values are shown as the mean ± SEM. aP < 0.05 thrombin vs. 
control.Journal of Inflammation 2009, 6:4 http://www.journal-inflammation.com/content/6/1/4
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Thrombin stimulates angiogenic growth hormone secretion predominately from primary cultures of newly differentiated  human adipocytes Figure 3
Thrombin stimulates angiogenic growth hormone secretion predominately from primary cultures of newly 
differentiated human adipocytes. Cultures of adipose tissue (n = 5), newly differentiated adipocytes (n = 5) or preadi-
pocytes (n = 3) were stimulated with thrombin (1 U/ml) or thrombin (10 U/ml) in the presence or absence of a thrombin inhib-
itor (lepirudin) for 24 hours. PBS served as the negative control. The following growth factors were measured from the 
supernatants of the cultures. A) FGF-2; B) PDGF and; C) VEGF. Means ± SEM *P < 0.05 thrombin vs. PBS. ± P < 0.05 thrombin 
+ lepirudin vs. thrombin.
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cytokine production in our cell cultures for several rea-
sons. First, macrophages have a short-life span in culture
making survival unlikely in our cultures where preadi-
pocytes and differentiated adipocytes were stimulated
after ~3 weeks of culture conditions [25]. Second, isolated
S-V fractions were divided in order to keep half the cells in
an undifferentiated state while the other half was differen-
tiated. Given that conditions and time course were similar
at the time of study between fractions, it is likely that mac-
rophage quantity was similar. If there was macrophage
survival under both conditions, a similar secretion profile
would be expected.
We also found that thrombin mediated similar levels of
MCP-1 secretion in adipocytes and preadipocytes. This is
consistent with other studies showing that cells from the
S-V fraction or preadipocytes are a major source of MCP-
1 secretion even though adipocytes also secrete MCP-1
[29-31]. The increase in MCP-1 secretion from our adi-
pocytes cultures may be from the adipocytes themselves
or from the number of preadipocytes cells in adipocytes
cultures that did not undergo differentiation.
Finally, we have shown that thrombin increases the secre-
tion of VEGF from adipocytes and preadipocytes cultures.
However, VEGF was higher in preadipocytes than adi-
pocytes suggesting VEGF may be preferentially secreted
from these cell types. This is consistent with other studies
indicating adipocytes have VEGF secretion capabilities in
response to neurohumoral factors such as insulin but that
non-adipocytes are the main secretors of VEGF [28-32].
Taken together with other studies that show preadipocytes
induces VEGF release in response to adipocytes differenti-
ation [33], our studies support the conclusion that both
cell types contributes to VEGF secretion. Thrombin is a
known stimulus for angiogenesis; therefore, thrombin-
mediated VEGF from preadipocytes and adipocytes may
be important for the angiogenesis that occurs during adi-
pogenesis and adipose expansion. Lepirudin, a direct
thrombin inhibitor abolished the thrombin-mediated
increase of IL-1β, IL-6, MCP-1 and TNF-α secretion along
with VEGF suggesting that cytokine and angiogenic
growth hormone secretion (Figure 2 and Figure 3) in our
studies was related to the interaction of thrombin with its
receptor, PAR4, in adipocytes.
Even though there was a trend towards increased secretion
of IL-1β, IL-6, MCP-1 and TNF-α in thrombin stimulated
adipose tissue, it did not reach significance. However, the
baseline production in these tissues was higher than our
cell culture measurements (adipocytes and preadipocytes)
suggesting that the contribution of cytokine production
from the non-adipocyte components of adipose tissue
(i.e. endothelial cell and macrophages) are additive. The
contribution of cytokine production from adipocytes
should not be dismissed since 1) cytokine secretion even
at low levels may be physiologically relevant and 2) most
cytokines have autorcrine and paracrine signalling such
that the localized effects of these compounds for vascular
and adipocyte function. Thrombin is known to stimulate
IL-1β and TNF-α secretion from endothelial cells, mono-
cytes, and fibroblasts which are residential cells within
adipose tissue supporting previous reports that these cell
types contribute to cytokine production in human adi-
pose tissue [9,11].
Inflammatory Cytokines and Adipose Tissue
Several inflammatory cytokines including TNF-α, IL-1β,
IL-6, and MCP-1 are released from adipocytes. These fac-
tors are also increased in obesity and contribute to insulin
resistance and atherosclerosis [34,35]. Thrombin activa-
tion of adipose cells may contribute to the circulating
inflammatory cytokines and insulin resistance found in
obese individuals. It is also possible that the inflamma-
tory phenotype induced by thrombin in obesity promotes
vascular inflammation and endothelial dysfunction
thereby advancing atherosclerosis. Thrombin activates
NF-κB thereby up-regulating a variety of cytokines in
other tissues and cells [3], a mechanism that may signal
thrombin-mediated release of inflammatory cytokines
from adipose tissue. Our results support the conclusion
that thrombin may contribute to the inflammatory state
by increasing IL-1β, IL-6, MCP-1, TNF-α in adipose tissue.
Angiogenic Growth Factors and Adipose Tissue
Angiogenesis plays an important role in atherosclerosis
and adipose tissue expansion [36]. The specific role of
VEGF in adipose angiogenesis and whether the enhanced
levels of coagulation factors associated with obesity
increase VEGF release by adipose tissue and thus contrib-
ute to angiogenesis is unknown. However, we have shown
that thrombin increases the secretion of growth hormones
(FGF-2, PDGF, and VEGF) from adipocytes and VEFG
from adipose tissue which suggests that thrombin may
contribute to angiogenic process in visceral adipose tissue.
Future studies are needed to explore the contribution of
adipocyte derived growth factors to preadipocyte differen-
tiation and angiogenesis in obesity.
Study Limitations
There are several limitations of this study. First, we did not
measure thrombin-mediated cytokine release from a
homogenous cell line where variability may be mini-
mized. On the other hand homogenous cell cultures make
it difficult to mimic the complexity and chronicity of dis-
ease processes such as obesity even though we might
expect less variation. Even though the cell culture condi-
tions were kept constant and grown to a similar maturity,
there was a lot of variability in the basal secretion of
cytokines and growth factors between samples indicating
that the variability is most likely due to the genetic heter-
ogeneity of the human tissues. Despite this limitation,Journal of Inflammation 2009, 6:4 http://www.journal-inflammation.com/content/6/1/4
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none of our patients had coagulation disorders, heart dis-
ease, or morbid obesity that may have confounded our
results. Second, tissue was obtained from discarded speci-
mens so it was impossible to obtain comprehensive clini-
cal data on our patient population making it difficult to
correct for the physiological confounding effects of our
subject population such as body fat distribution and
severity of disease. However, all subjects had a BMI<34
and no cardiovascular risk factors, thereby eliminating
most the confounding effects of overt obesity and cardio-
vascular disease on cytokine production from fat. Despite
this recruitment strategy, this study demonstrates an
increase in thrombin-mediated cytokine secretion from
which future studies will focus on the effects of age, sex,
and body fat distribution on the physiological responses
of adipose to thrombin. Third, our study was limited to
the effect of thrombin on cytokine and angiogenic growth
factor release from abdominal adipose. Since, other adi-
pose depots may respond differently, future studies may
focus on the inflammatory profile of other adipose depots
that may contribute to cardiovascular disease (e.g. pericar-
dial adipose). Fourth, our patient population was not
morbidly obese. This was an unavoidable limitation of
our study design using discarded and de-identified surgi-
cal samples. While most of the cytokines measured in this
study are elevated in obesity, it is unknown whether
thrombin induced cytokine release is dependent on the
patient's adipose tissue distribution profile making it dif-
ficult to discern the contribution of thrombin mediated
cytokines to obesity and other associated diseases (i.e. car-
diovascular disease). Future studies will determine rela-
tionships between the thrombin-mediated inflammatory
response, PAR 4 expression in isolated adipose tissue cell
types, and body adipose mass.
Conclusion
This study demonstrates the presence of PAR1 and PAR4
in adipose tissue and PAR4 in isolated populations of adi-
pocytes and preadipocytes. Thrombin stimulation of adi-
pocytes and preadipocytes increases pro-inflammatory
cytokines (IL-1β, IL-6, TNF-α, MCP-1) along with the ang-
iogenic growth factor (VEGF). Therefore, thrombin may
contribute to the inflammatory state associated with vis-
ceral adipose tissue.
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